f883d577befb92968530b2b07f64e7af12ce1725
ABL2.md
| ... | ... | @@ -42,4 +42,4 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/A |
| 42 | 42 | |
| 43 | 43 | |
| 44 | 44 | <!-- ORIGIN: russler-germainMutationsAssociatedProgression2023a --> |
| 45 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 45 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
BCL10.md
| ... | ... | @@ -68,6 +68,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/B |
| 68 | 68 | 2. *Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011 Jul 27;476(7360):298-303. doi: 10.1038/nature10351. PMID: 21796119; PMCID: PMC3210554.* |
| 69 | 69 | |
| 70 | 70 | <!-- ORIGIN: morinFrequentMutationHistonemodifying2011 --> |
| 71 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 71 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 72 | 72 | <!-- MZL: spinaGeneticsNodalMarginal2016b --> |
| 73 | 73 | <!-- DLBCL: morinFrequentMutationHistonemodifying2011 --> |
BL_FL_DLBCL_sankey_methods.md
| ... | ... | @@ -103,8 +103,8 @@ WGS, 2018 WGS studies, 20 |
| 103 | 103 | Arthur 2018, DLBCL Tier 2, 12 |
| 104 | 104 | Arthur 2018, DLBCL Tier 1, 8 |
| 105 | 105 | |
| 106 | -RNA-seq/exome,2019 RNA-seq/exome studies,47 |
|
| 107 | -2019 RNA-seq/exome studies, Panea 2019, 47 |
|
| 106 | +RNA-seq/exome,2019 ,47 |
|
| 107 | +2019 , Panea 2019, 47 |
|
| 108 | 108 | Panea 2019, BL Tier 2, 43 |
| 109 | 109 | Panea 2019, BL Tier 1, 4 |
| 110 | 110 |
BL_genes.md
| ... | ... | @@ -47,201 +47,201 @@ WGS, Thomas 2023, 5 |
| 47 | 47 | |
| 48 | 48 | ### *29 total* |
| 49 | 49 | |
| 50 | -| Gene | Tier | Relevant references | |
|
| 51 | -|:------------------:|:-------:|:---------------------------------------------------------------------------------| |
|
| 52 | -| [ARID1A](ARID1A) | 1 | Zhang et al. 2013; Love et al. 2012; Krysiak et al. 2017 | |
|
| 53 | -| [BCL7A](BCL7A) | 1, aSHM | Grande et al. 2019; Krysiak et al. 2017; Arthur et al. 2018 | |
|
| 54 | -| [BMP7](BMP7) | 1 | Panea et al. 2019 | |
|
| 55 | -| [CCND3](CCND3) | 1 | Richter et al. 2012; Morin et al. 2011 | |
|
| 56 | -| [CHD8](CHD8) | 1 | Grande et al. 2019; Reddy et al. 2017 | |
|
| 57 | -| [DDX3X](DDX3X) | 1 | Schmitz et al. 2018, 2012 | |
|
| 58 | -| [EIF4A1](EIF4A1) | 1 | Panea et al. 2019 | |
|
| 59 | -| [EPPK1](EPPK1) | 1 | Panea et al. 2019 | |
|
| 60 | -| [FBXO11](FBXO11) | 1 | Richter et al. 2012; Hübschmann et al. 2021 | |
|
| 61 | -| [FOXO1](FOXO1) | 1 | Schmitz et al. 2012; Morin et al. 2011 | |
|
| 62 | -| [GNA13](GNA13) | 1 | Morin et al. 2011; Love et al. 2012 | |
|
| 63 | -| [GNAI2](GNAI2) | 1 | Grande et al. 2019; Morin et al. 2013 | |
|
| 64 | -| [HNRNPU](HNRNPU) | 1, aSHM | Panea et al. 2019; Reddy et al. 2017 | |
|
| 65 | -| [ID3](ID3) | 1 | Schmitz et al. 2012; Richter et al. 2012 | |
|
| 66 | -| [KMT2D](KMT2D) | 1 | Grande et al. 2019; Morin et al. 2011; Beà et al. 2013 | |
|
| 67 | -| [MYC](MYC) | 1, aSHM | L. Pasqualucci et al. 2001; Johnston and Carroll 1992 | |
|
| 68 | -| [P2RY8](P2RY8) | 1 | Lohr et al. 2012; Muppidi et al. 2014 | |
|
| 69 | -| [PHF6](PHF6) | 1 | Reddy et al. 2017; Thomas et al. 2023 | |
|
| 70 | -| [PTEN](PTEN) | 1 | Love et al. 2012 | |
|
| 71 | -| [RFX7](RFX7) | 1 | Grande et al. 2019 | |
|
| 72 | -| [RHOA](RHOA) | 1 | Richter et al. 2012 | |
|
| 73 | -| [SIN3A](SIN3A) | 1 | Grande et al. 2019 | |
|
| 74 | -| [SMARCA4](SMARCA4) | 1 | Richter et al. 2012; Zhang et al. 2013; Nadeu et al. 2020; Krysiak et al. 2017 | |
|
| 75 | -| [TCF3](TCF3) | 1 | Schmitz et al. 2012 | |
|
| 76 | -| [TCL1A](TCL1A) | 1, aSHM | Grande et al. 2019 | |
|
| 77 | -| [TFAP4](TFAP4) | 1 | Grande et al. 2019 | |
|
| 78 | -| [TP53](TP53) | 1 | Morin et al. 2011; Wilda et al. 2004; Beà et al. 2013 | |
|
| 79 | -| [USP7](USP7) | 1 | Grande et al. 2019 | |
|
| 80 | -| [WNK1](WNK1) | 1 | Thomas et al. 2023; Hübschmann et al. 2021 | |
|
| 50 | +| Gene | Tier | Relevant references | |
|
| 51 | +|:------------------:|:-------:|:---------------------------------------------------------------------------------------------------| |
|
| 52 | +| [ARID1A](ARID1A) | 1 | Rossi et al. 2012; Wienand et al. 2019; Zhang et al. 2013; Love et al. 2012; Krysiak et al. 2017 | |
|
| 53 | +| [BCL7A](BCL7A) | 1, aSHM | Krysiak et al. 2017; Arthur et al. 2018; Grande et al. 2019; Reichel et al. 2015 | |
|
| 54 | +| [BMP7](BMP7) | 1 | Panea et al. 2019 | |
|
| 55 | +| [CCND3](CCND3) | 1 | Desch et al. 2020; Richter et al. 2012; Jallades et al. 2017; Morin et al. 2011 | |
|
| 56 | +| [CHD8](CHD8) | 1 | Reddy et al. 2017; Grande et al. 2019 | |
|
| 57 | +| [DDX3X](DDX3X) | 1 | Schmitz et al. 2012, 2018; Mottok et al. 2019 | |
|
| 58 | +| [EIF4A1](EIF4A1) | 1 | Panea et al. 2019 | |
|
| 59 | +| [EPPK1](EPPK1) | 1 | Panea et al. 2019 | |
|
| 60 | +| [FBXO11](FBXO11) | 1 | Hübschmann et al. 2021; Parry et al. 2013; Richter et al. 2012 | |
|
| 61 | +| [FOXO1](FOXO1) | 1 | Schmitz et al. 2012; Morin et al. 2011; Duns et al. 2021 | |
|
| 62 | +| [GNA13](GNA13) | 1 | Reichel et al. 2015; Love et al. 2012; Morin et al. 2011 | |
|
| 63 | +| [GNAI2](GNAI2) | 1 | Grande et al. 2019; Morin et al. 2013 | |
|
| 64 | +| [HNRNPU](HNRNPU) | 1, aSHM | Panea et al. 2019; Reddy et al. 2017 | |
|
| 65 | +| [ID3](ID3) | 1 | Schmitz et al. 2012; Spina et al. 2016; Richter et al. 2012 | |
|
| 66 | +| [KMT2D](KMT2D) | 1 | Desch et al. 2020; Rossi et al. 2012; Morin et al. 2011; Beà et al. 2013; Grande et al. 2019 | |
|
| 67 | +| [MYC](MYC) | 1, aSHM | Johnston and Carroll 1992; L. Pasqualucci et al. 2001; Duns et al. 2021; Jallades et al. 2017 | |
|
| 68 | +| [P2RY8](P2RY8) | 1 | Muppidi et al. 2014; Lohr et al. 2012 | |
|
| 69 | +| [PHF6](PHF6) | 1 | Thomas et al. 2023; Reddy et al. 2017 | |
|
| 70 | +| [PTEN](PTEN) | 1 | Love et al. 2012 | |
|
| 71 | +| [RFX7](RFX7) | 1 | Grande et al. 2019 | |
|
| 72 | +| [RHOA](RHOA) | 1 | Richter et al. 2012 | |
|
| 73 | +| [SIN3A](SIN3A) | 1 | Grande et al. 2019; Rossi et al. 2012 | |
|
| 74 | +| [SMARCA4](SMARCA4) | 1 | Richter et al. 2012; Nadeu et al. 2020; Zhang et al. 2013; Krysiak et al. 2017 | |
|
| 75 | +| [TCF3](TCF3) | 1 | Schmitz et al. 2012 | |
|
| 76 | +| [TCL1A](TCL1A) | 1, aSHM | Grande et al. 2019 | |
|
| 77 | +| [TFAP4](TFAP4) | 1 | Grande et al. 2019 | |
|
| 78 | +| [TP53](TP53) | 1 | Rossi et al. 2012; Wilda et al. 2004; Tiacci et al. 2018; Beà et al. 2013; Morin et al. 2011 | |
|
| 79 | +| [USP7](USP7) | 1 | Grande et al. 2019 | |
|
| 80 | +| [WNK1](WNK1) | 1 | Hübschmann et al. 2021; Thomas et al. 2023; Jallades et al. 2017 | |
|
| 81 | 81 | |
| 82 | 82 | ## Tier 2 BL genes |
| 83 | 83 | |
| 84 | 84 | ### *157 total* |
| 85 | 85 | |
| 86 | -| Gene | Tier | Relevant references | |
|
| 87 | -|:----------------------:|:-------:|:------------------------------------------------------------------------------| |
|
| 88 | -| [ACAD9](ACAD9) | 2 | Love et al. 2012 | |
|
| 89 | -| [ACE](ACE) | 2 | Love et al. 2012 | |
|
| 90 | -| [ADAMTS5](ADAMTS5) | 2 | Burkhardt et al. 2022 | |
|
| 91 | -| [ADNP](ADNP) | 2 | Burkhardt et al. 2022 | |
|
| 92 | -| [AGO4](AGO4) | 2 | Burkhardt et al. 2022 | |
|
| 93 | -| [ALPK2](ALPK2) | 2 | Panea et al. 2019 | |
|
| 94 | -| [ARHGEF1](ARHGEF1) | 2 | Muppidi et al. 2014 | |
|
| 95 | -| [ATP2C2](ATP2C2) | 2 | Love et al. 2012 | |
|
| 96 | -| [BACH2](BACH2) | 2, aSHM | Grande et al. 2019 | |
|
| 97 | -| [BCL2](BCL2) | 2, aSHM | Tanaka et al. 1992; Burkhardt et al. 2022; Morin et al. 2011 | |
|
| 98 | -| [BCL6](BCL6) | 2, aSHM | Morin et al. 2011; Love et al. 2012 | |
|
| 99 | -| [BRAF](BRAF) | 2 | Love et al. 2012; Tiacci et al. 2011 | |
|
| 100 | -| [BRD4](BRD4) | 2 | Love et al. 2012 | |
|
| 101 | -| [BTG1](BTG1) | 2, aSHM | Morin et al. 2011; Burkhardt et al. 2022 | |
|
| 102 | -| [BTG2](BTG2) | 2, aSHM | Love et al. 2012; Morin et al. 2011 | |
|
| 103 | -| [C16orf48](C16orf48) | 2 | Schmitz et al. 2012 | |
|
| 104 | -| [C6orf27](C6orf27) | 2 | Love et al. 2012 | |
|
| 105 | -| [CAD](CAD) | 2 | Love et al. 2012 | |
|
| 106 | -| [CARD11](CARD11) | 2 | Morin et al. 2011; Panea et al. 2019; Wu et al. 2016; Lenz et al. 2008 | |
|
| 107 | -| [CARD4](CARD4) | 2 | Love et al. 2012 | |
|
| 108 | -| [CCNF](CCNF) | 2 | Abate et al. 2015 | |
|
| 109 | -| [CCT6B](CCT6B) | 2 | Love et al. 2012 | |
|
| 110 | -| [CD79A](CD79A) | 2 | Burkhardt et al. 2022 | |
|
| 111 | -| [CD79B](CD79B) | 2 | Panea et al. 2019; Morin et al. 2011 | |
|
| 112 | -| [CD83](CD83) | 2, aSHM | Morin et al. 2013; Russler-Germain et al. 2023; Panea et al. 2019 | |
|
| 113 | -| [CDC73](CDC73) | 2 | Love et al. 2012; Reddy et al. 2017 | |
|
| 114 | -| [CDH17](CDH17) | 2 | Love et al. 2012 | |
|
| 115 | -| [CDKN2A](CDKN2A) | 2 | Grande et al. 2019; Morin et al. 2013 | |
|
| 116 | -| [CDKN2C](CDKN2C) | 2 | Thomas et al. 2023 | |
|
| 117 | -| [CHD4](CHD4) | 2 | Burkhardt et al. 2022 | |
|
| 118 | -| [COL4A2](COL4A2) | 2 | Love et al. 2012 | |
|
| 119 | -| [CPXM2](CPXM2) | 2 | Burkhardt et al. 2022 | |
|
| 120 | -| [CREBBP](CREBBP) | 2 | Laura Pasqualucci, Dominguez-Sola, et al. 2011; Love et al. 2012 | |
|
| 121 | -| [CTCF](CTCF) | 2 | Panea et al. 2019 | |
|
| 122 | -| [CXCR4](CXCR4) | 2, aSHM | Panea et al. 2019; Khodabakhshi et al. 2012; Krysiak et al. 2017 | |
|
| 123 | -| [CYB5D1](CYB5D1) | 2 | Love et al. 2012 | |
|
| 124 | -| [CYP4F22](CYP4F22) | 2 | Love et al. 2012 | |
|
| 125 | -| [DHCR7](DHCR7) | 2 | Schmitz et al. 2012 | |
|
| 126 | -| [DLGAP1](DLGAP1) | 2 | Love et al. 2012 | |
|
| 127 | -| [DNMT1](DNMT1) | 2 | Panea et al. 2019 | |
|
| 128 | -| [DTX1](DTX1) | 2, aSHM | Schmitz et al. 2018; Panea et al. 2019 | |
|
| 129 | -| [E2F2](E2F2) | 2 | Burkhardt et al. 2022 | |
|
| 130 | -| [EBF1](EBF1) | 2, aSHM | Thomas et al. 2023; Bohle et al. 2013 | |
|
| 131 | -| [EDNRB](EDNRB) | 2 | Burkhardt et al. 2022 | |
|
| 132 | -| [EHD1](EHD1) | 2 | Thomas et al. 2023 | |
|
| 133 | -| [EIF2C4](EIF2C4) | 2 | Love et al. 2012 | |
|
| 134 | -| [ELP2](ELP2) | 2 | Schmitz et al. 2012 | |
|
| 135 | -| [EML2](EML2) | 2 | Love et al. 2012 | |
|
| 136 | -| [ENTPD3](ENTPD3) | 2 | Love et al. 2012 | |
|
| 137 | -| [EP300](EP300) | 2 | Laura Pasqualucci, Dominguez-Sola, et al. 2011; Panea et al. 2019 | |
|
| 138 | -| [EPHB2](EPHB2) | 2 | Love et al. 2012 | |
|
| 139 | -| [ERAP1](ERAP1) | 2 | Burkhardt et al. 2022 | |
|
| 140 | -| [ETS1](ETS1) | 2, aSHM | Morin et al. 2011; Panea et al. 2019 | |
|
| 141 | -| [EXOSC6](EXOSC6) | 2 | Schmitz et al. 2012 | |
|
| 142 | -| [EZH2](EZH2) | 2 | Love et al. 2012; Morin et al. 2010 | |
|
| 143 | -| [FAM129B](FAM129B) | 2 | Love et al. 2012 | |
|
| 144 | -| [FGFR3](FGFR3) | 2 | Love et al. 2012 | |
|
| 145 | -| [FLYWCH1](FLYWCH1) | 2 | Schmitz et al. 2012 | |
|
| 146 | -| [FTCD](FTCD) | 2 | Love et al. 2012 | |
|
| 147 | -| [FZD3](FZD3) | 2 | Panea et al. 2019 | |
|
| 148 | -| [GGTLA4](GGTLA4) | 2 | Love et al. 2012 | |
|
| 149 | -| [GRB2](GRB2) | 2 | Laura Pasqualucci, Trifonov, et al. 2011; Panea et al. 2019 | |
|
| 150 | -| [GRIK5](GRIK5) | 2 | Love et al. 2012 | |
|
| 151 | -| [GTSE1](GTSE1) | 2 | Schmitz et al. 2012 | |
|
| 152 | -| [HIST1H1C](HIST1H1C) | 2, aSHM | Morin et al. 2011; Panea et al. 2019 | |
|
| 153 | -| [HIST1H1E](HIST1H1E) | 2, aSHM | Grande et al. 2019; Morin et al. 2013; Krysiak et al. 2017 | |
|
| 154 | -| [HIST1H2AG](HIST1H2AG) | 2, aSHM | Panea et al. 2019; Morin et al. 2013; Krysiak et al. 2017 | |
|
| 155 | -| [HIST1H2AM](HIST1H2AM) | 2, aSHM | Panea et al. 2019; Krysiak et al. 2017 | |
|
| 156 | -| [HIST1H2BK](HIST1H2BK) | 2, aSHM | Panea et al. 2019 | |
|
| 157 | -| [HIST1H3D](HIST1H3D) | 2, aSHM | Panea et al. 2019 | |
|
| 158 | -| [HIST1H3H](HIST1H3H) | 2, aSHM | Panea et al. 2019 | |
|
| 159 | -| [HIST1H3I](HIST1H3I) | 2, aSHM | Krysiak et al. 2017; Panea et al. 2019 | |
|
| 160 | -| [HIST1H3J](HIST1H3J) | 2, aSHM | Panea et al. 2019 | |
|
| 161 | -| [HIST1H4J](HIST1H4J) | 2, aSHM | Panea et al. 2019 | |
|
| 162 | -| [HLA-A](HLA-A) | 2 | | |
|
| 163 | -| [HLA-B](HLA-B) | 2 | | |
|
| 164 | -| [HLA-DMB](HLA-DMB) | 2 | | |
|
| 165 | -| [HLA-DQB1](HLA-DQB1) | 2 | Burkhardt et al. 2022 | |
|
| 166 | -| [ICK](ICK) | 2 | Love et al. 2012 | |
|
| 167 | -| [IGLL5](IGLL5) | 2, aSHM | Panea et al. 2019; Russler-Germain et al. 2023 | |
|
| 168 | -| [IKZF3](IKZF3) | 2, aSHM | Morin et al. 2013; Panea et al. 2019 | |
|
| 169 | -| [IRF8](IRF8) | 2, aSHM | Panea et al. 2019; Morin et al. 2011 | |
|
| 170 | -| [ITPR3](ITPR3) | 2 | Love et al. 2012 | |
|
| 171 | -| [KANK2](KANK2) | 2 | Schmitz et al. 2012 | |
|
| 172 | -| [KCNK10](KCNK10) | 2 | Panea et al. 2019 | |
|
| 173 | -| [KIFC3](KIFC3) | 2 | Love et al. 2012 | |
|
| 174 | -| [KLHL26](KLHL26) | 2 | Burkhardt et al. 2022 | |
|
| 175 | -| [KLHL6](KLHL6) | 2, aSHM | Morin et al. 2011; Panea et al. 2019 | |
|
| 176 | -| [KMT2C](KMT2C) | 2 | Zhou et al. 2019; Zhang et al. 2013; Zhang et al. 2014 | |
|
| 177 | -| [LTB](LTB) | 2, aSHM | Chapuy et al. 2018; Panea et al. 2019 | |
|
| 178 | -| [MAP3K6](MAP3K6) | 2 | Love et al. 2012 | |
|
| 179 | -| [MCL1](MCL1) | 2 | Panea et al. 2019; Reddy et al. 2017 | |
|
| 180 | -| [MIR142](MIR142) | 2, aSHM | Grande et al. 2019; Kwanhian et al. 2012 | |
|
| 181 | -| [MKI67](MKI67) | 2 | Schmitz et al. 2012; Russler-Germain et al. 2023 | |
|
| 182 | -| [MME](MME) | 2 | Panea et al. 2019 | |
|
| 183 | -| [MTOR](MTOR) | 2 | Zhang et al. 2013; Panea et al. 2019 | |
|
| 184 | -| [MYH10](MYH10) | 2 | Love et al. 2012 | |
|
| 185 | -| [MYO18A](MYO18A) | 2 | Schmitz et al. 2012 | |
|
| 186 | -| [NBEAL1](NBEAL1) | 2 | Love et al. 2012 | |
|
| 187 | -| [NCOR2](NCOR2) | 2 | Schmitz et al. 2012 | |
|
| 188 | -| [NOA1](NOA1) | 2 | Burkhardt et al. 2022 | |
|
| 189 | -| [NOTCH1](NOTCH1) | 2 | Beà et al. 2013; Love et al. 2012; Laura Pasqualucci, Trifonov, et al. 2011 | |
|
| 190 | -| [NOTCH2](NOTCH2) | 2 | Trøen et al. 2008; Beà et al. 2013; Panea et al. 2019 | |
|
| 191 | -| [NRXN2](NRXN2) | 2 | Love et al. 2012 | |
|
| 192 | -| [P2RY2](P2RY2) | 2 | Love et al. 2012 | |
|
| 193 | -| [PABPC4L](PABPC4L) | 2 | Panea et al. 2019 | |
|
| 194 | -| [PC](PC) | 2 | Love et al. 2012 | |
|
| 195 | -| [PCBP1](PCBP1) | 2 | Schmitz et al. 2012 | |
|
| 196 | -| [PCDHA11](PCDHA11) | 2 | Panea et al. 2019 | |
|
| 197 | -| [PDCD11](PDCD11) | 2 | Schmitz et al. 2012 | |
|
| 198 | -| [PDZRN3](PDZRN3) | 2 | Panea et al. 2019 | |
|
| 199 | -| [PIK3R1](PIK3R1) | 2 | Panea et al. 2019; Zhang et al. 2013 | |
|
| 200 | -| [PIM1](PIM1) | 2, aSHM | L. Pasqualucci et al. 2001; Burkhardt et al. 2022 | |
|
| 201 | -| [PLCG2](PLCG2) | 2 | Panea et al. 2019 | |
|
| 202 | -| [POLRMT](POLRMT) | 2 | Love et al. 2012 | |
|
| 203 | -| [POR](POR) | 2 | Love et al. 2012 | |
|
| 204 | -| [PPP6R2](PPP6R2) | 2 | Burkhardt et al. 2022 | |
|
| 205 | -| [PREX1](PREX1) | 2 | Burkhardt et al. 2022 | |
|
| 206 | -| [PRSS22](PRSS22) | 2 | Love et al. 2012 | |
|
| 207 | -| [PTPRN](PTPRN) | 2 | Love et al. 2012 | |
|
| 208 | -| [PXDNL](PXDNL) | 2 | Panea et al. 2019 | |
|
| 209 | -| [RAC2](RAC2) | 2 | Panea et al. 2019; Hübschmann et al. 2021 | |
|
| 210 | -| [RANBP6](RANBP6) | 2 | Love et al. 2012 | |
|
| 211 | -| [RBP3](RBP3) | 2 | Love et al. 2012 | |
|
| 212 | -| [RET](RET) | 2 | Love et al. 2012 | |
|
| 213 | -| [REV3L](REV3L) | 2 | Burkhardt et al. 2022 | |
|
| 214 | -| [RNF144B](RNF144B) | 2 | Panea et al. 2019 | |
|
| 215 | -| [RPL10](RPL10) | 2 | Burkhardt et al. 2022 | |
|
| 216 | -| [S1PR2](S1PR2) | 2, aSHM | Muppidi et al. 2014; Morin et al. 2011 | |
|
| 217 | -| [SAL3](SAL3) | 2 | Burkhardt et al. 2022 | |
|
| 218 | -| [SALL3](SALL3) | 2 | Zhang et al. 2014; Love et al. 2012 | |
|
| 219 | -| [SAPS2](SAPS2) | 2 | Love et al. 2012 | |
|
| 220 | -| [SBF1](SBF1) | 2 | Love et al. 2012 | |
|
| 221 | -| [SF3B1](SF3B1) | 2 | Love et al. 2012 | |
|
| 222 | -| [SHANK1](SHANK1) | 2 | Love et al. 2012 | |
|
| 223 | -| [SLC29A2](SLC29A2) | 2 | Love et al. 2012 | |
|
| 224 | -| [SNTB2](SNTB2) | 2 | Panea et al. 2019 | |
|
| 225 | -| [SP3](SP3) | 2 | Panea et al. 2019 | |
|
| 226 | -| [SYNCRIP](SYNCRIP) | 2 | Panea et al. 2019 | |
|
| 227 | -| [SYNGAP1](SYNGAP1) | 2 | Love et al. 2012 | |
|
| 228 | -| [TBC1D9B](TBC1D9B) | 2 | Love et al. 2012 | |
|
| 229 | -| [TET2](TET2) | 2 | Albuquerque et al. 2017; Panea et al. 2019 | |
|
| 230 | -| [TIGD6](TIGD6) | 2 | Love et al. 2012 | |
|
| 231 | -| [TOP2A](TOP2A) | 2 | Schmitz et al. 2012 | |
|
| 232 | -| [TPST2](TPST2) | 2 | Love et al. 2012 | |
|
| 233 | -| [TTN](TTN) | 2 | Burkhardt et al. 2022 | |
|
| 234 | -| [VWA7](VWA7) | 2 | Burkhardt et al. 2022 | |
|
| 235 | -| [WDR7](WDR7) | 2 | Panea et al. 2019 | |
|
| 236 | -| [WDR90](WDR90) | 2 | Schmitz et al. 2012 | |
|
| 237 | -| [WHAMM](WHAMM) | 2 | Schmitz et al. 2012 | |
|
| 238 | -| [WNK2](WNK2) | 2 | Panea et al. 2019 | |
|
| 239 | -| [YY1AP1](YY1AP1) | 2 | Schmitz et al. 2012 | |
|
| 240 | -| [ZAN](ZAN) | 2 | Burkhardt et al. 2022 | |
|
| 241 | -| [ZBTB7A](ZBTB7A) | 2 | Reddy et al. 2017; Burkhardt et al. 2022 | |
|
| 242 | -| [ZFP36L1](ZFP36L1) | 2, aSHM | Panea et al. 2019; Morin et al. 2011 | |
|
| 243 | -| [ZNF229](ZNF229) | 2 | Love et al. 2012 | |
|
| 244 | -| [ZNF85](ZNF85) | 2 | Burkhardt et al. 2022 | |
|
| 86 | +| Gene | Tier | Relevant references | |
|
| 87 | +|:----------------------:|:-------:|:--------------------------------------------------------------------------------------------------------| |
|
| 88 | +| [ACAD9](ACAD9) | 2 | Love et al. 2012 | |
|
| 89 | +| [ACE](ACE) | 2 | Love et al. 2012 | |
|
| 90 | +| [ADAMTS5](ADAMTS5) | 2 | Burkhardt et al. 2022 | |
|
| 91 | +| [ADNP](ADNP) | 2 | Burkhardt et al. 2022 | |
|
| 92 | +| [AGO4](AGO4) | 2 | Burkhardt et al. 2022 | |
|
| 93 | +| [ALPK2](ALPK2) | 2 | Panea et al. 2019 | |
|
| 94 | +| [ARHGEF1](ARHGEF1) | 2 | Muppidi et al. 2014 | |
|
| 95 | +| [ATP2C2](ATP2C2) | 2 | Love et al. 2012 | |
|
| 96 | +| [BACH2](BACH2) | 2, aSHM | Grande et al. 2019 | |
|
| 97 | +| [BCL2](BCL2) | 2, aSHM | Sarkozy et al. 2021; Tanaka et al. 1992; Burkhardt et al. 2022; Morin et al. 2011 | |
|
| 98 | +| [BCL6](BCL6) | 2, aSHM | Love et al. 2012; Morin et al. 2011 | |
|
| 99 | +| [BRAF](BRAF) | 2 | Tiacci et al. 2011; Love et al. 2012 | |
|
| 100 | +| [BRD4](BRD4) | 2 | Love et al. 2012 | |
|
| 101 | +| [BTG1](BTG1) | 2, aSHM | Sarkozy et al. 2021; Burkhardt et al. 2022; Morin et al. 2011 | |
|
| 102 | +| [BTG2](BTG2) | 2, aSHM | Love et al. 2012; Morin et al. 2011 | |
|
| 103 | +| [C16orf48](C16orf48) | 2 | Schmitz et al. 2012 | |
|
| 104 | +| [C6orf27](C6orf27) | 2 | Love et al. 2012 | |
|
| 105 | +| [CAD](CAD) | 2 | Love et al. 2012 | |
|
| 106 | +| [CARD11](CARD11) | 2 | Wu et al. 2016; Panea et al. 2019; Morin et al. 2011; Yan et al. 2012; Lenz et al. 2008 | |
|
| 107 | +| [CARD4](CARD4) | 2 | Love et al. 2012 | |
|
| 108 | +| [CCNF](CCNF) | 2 | Abate et al. 2015 | |
|
| 109 | +| [CCT6B](CCT6B) | 2 | Love et al. 2012 | |
|
| 110 | +| [CD79A](CD79A) | 2 | Burkhardt et al. 2022; Rossi et al. 2012 | |
|
| 111 | +| [CD79B](CD79B) | 2 | Morin et al. 2011; Panea et al. 2019 | |
|
| 112 | +| [CD83](CD83) | 2, aSHM | Russler-Germain et al. 2023; Morin et al. 2013; Duns et al. 2021; Panea et al. 2019 | |
|
| 113 | +| [CDC73](CDC73) | 2 | Reddy et al. 2017; Love et al. 2012 | |
|
| 114 | +| [CDH17](CDH17) | 2 | Love et al. 2012 | |
|
| 115 | +| [CDKN2A](CDKN2A) | 2 | Morin et al. 2013; Spina et al. 2016; Grande et al. 2019 | |
|
| 116 | +| [CDKN2C](CDKN2C) | 2 | Thomas et al. 2023 | |
|
| 117 | +| [CHD4](CHD4) | 2 | Burkhardt et al. 2022 | |
|
| 118 | +| [COL4A2](COL4A2) | 2 | Love et al. 2012 | |
|
| 119 | +| [CPXM2](CPXM2) | 2 | Burkhardt et al. 2022 | |
|
| 120 | +| [CREBBP](CREBBP) | 2 | Parry et al. 2013; Love et al. 2012; Laura Pasqualucci, Dominguez-Sola, et al. 2011; Duns et al. 2021 | |
|
| 121 | +| [CTCF](CTCF) | 2 | Panea et al. 2019 | |
|
| 122 | +| [CXCR4](CXCR4) | 2, aSHM | Krysiak et al. 2017; Panea et al. 2019; Khodabakhshi et al. 2012 | |
|
| 123 | +| [CYB5D1](CYB5D1) | 2 | Love et al. 2012 | |
|
| 124 | +| [CYP4F22](CYP4F22) | 2 | Love et al. 2012 | |
|
| 125 | +| [DHCR7](DHCR7) | 2 | Schmitz et al. 2012 | |
|
| 126 | +| [DLGAP1](DLGAP1) | 2 | Love et al. 2012 | |
|
| 127 | +| [DNMT1](DNMT1) | 2 | Panea et al. 2019 | |
|
| 128 | +| [DTX1](DTX1) | 2, aSHM | Gomez et al. 2023; Panea et al. 2019; Schmitz et al. 2018; Rossi et al. 2012 | |
|
| 129 | +| [E2F2](E2F2) | 2 | Burkhardt et al. 2022 | |
|
| 130 | +| [EBF1](EBF1) | 2, aSHM | Reichel et al. 2015; Bohle et al. 2013; Thomas et al. 2023 | |
|
| 131 | +| [EDNRB](EDNRB) | 2 | Burkhardt et al. 2022 | |
|
| 132 | +| [EHD1](EHD1) | 2 | Thomas et al. 2023 | |
|
| 133 | +| [EIF2C4](EIF2C4) | 2 | Love et al. 2012 | |
|
| 134 | +| [ELP2](ELP2) | 2 | Schmitz et al. 2012 | |
|
| 135 | +| [EML2](EML2) | 2 | Love et al. 2012 | |
|
| 136 | +| [ENTPD3](ENTPD3) | 2 | Love et al. 2012 | |
|
| 137 | +| [EP300](EP300) | 2 | Panea et al. 2019; Rossi et al. 2012; Laura Pasqualucci, Dominguez-Sola, et al. 2011 | |
|
| 138 | +| [EPHB2](EPHB2) | 2 | Love et al. 2012 | |
|
| 139 | +| [ERAP1](ERAP1) | 2 | Burkhardt et al. 2022 | |
|
| 140 | +| [ETS1](ETS1) | 2, aSHM | Morin et al. 2011; Panea et al. 2019 | |
|
| 141 | +| [EXOSC6](EXOSC6) | 2 | Schmitz et al. 2012 | |
|
| 142 | +| [EZH2](EZH2) | 2 | Mottok et al. 2019; Love et al. 2012; Morin et al. 2010 | |
|
| 143 | +| [FAM129B](FAM129B) | 2 | Love et al. 2012 | |
|
| 144 | +| [FGFR3](FGFR3) | 2 | Love et al. 2012 | |
|
| 145 | +| [FLYWCH1](FLYWCH1) | 2 | Schmitz et al. 2012 | |
|
| 146 | +| [FTCD](FTCD) | 2 | Love et al. 2012 | |
|
| 147 | +| [FZD3](FZD3) | 2 | Panea et al. 2019 | |
|
| 148 | +| [GGTLA4](GGTLA4) | 2 | Love et al. 2012 | |
|
| 149 | +| [GRB2](GRB2) | 2 | Panea et al. 2019; Laura Pasqualucci, Trifonov, et al. 2011 | |
|
| 150 | +| [GRIK5](GRIK5) | 2 | Love et al. 2012 | |
|
| 151 | +| [GTSE1](GTSE1) | 2 | Schmitz et al. 2012 | |
|
| 152 | +| [HIST1H1C](HIST1H1C) | 2, aSHM | Panea et al. 2019; Morin et al. 2011 | |
|
| 153 | +| [HIST1H1E](HIST1H1E) | 2, aSHM | Morin et al. 2013; Reichel et al. 2015; Grande et al. 2019; Krysiak et al. 2017 | |
|
| 154 | +| [HIST1H2AG](HIST1H2AG) | 2, aSHM | Krysiak et al. 2017; Panea et al. 2019; Morin et al. 2013; Rossi et al. 2012 | |
|
| 155 | +| [HIST1H2AM](HIST1H2AM) | 2, aSHM | Krysiak et al. 2017; Panea et al. 2019 | |
|
| 156 | +| [HIST1H2BK](HIST1H2BK) | 2, aSHM | Rossi et al. 2012; Panea et al. 2019 | |
|
| 157 | +| [HIST1H3D](HIST1H3D) | 2, aSHM | Panea et al. 2019 | |
|
| 158 | +| [HIST1H3H](HIST1H3H) | 2, aSHM | Panea et al. 2019 | |
|
| 159 | +| [HIST1H3I](HIST1H3I) | 2, aSHM | Panea et al. 2019; Krysiak et al. 2017 | |
|
| 160 | +| [HIST1H3J](HIST1H3J) | 2, aSHM | Panea et al. 2019 | |
|
| 161 | +| [HIST1H4J](HIST1H4J) | 2, aSHM | Mottok et al. 2019; Panea et al. 2019 | |
|
| 162 | +| [HLA-A](HLA-A) | 2 | Desch et al. 2020 | |
|
| 163 | +| [HLA-B](HLA-B) | 2 | Wienand et al. 2019 | |
|
| 164 | +| [HLA-DMB](HLA-DMB) | 2 | | |
|
| 165 | +| [HLA-DQB1](HLA-DQB1) | 2 | Burkhardt et al. 2022 | |
|
| 166 | +| [ICK](ICK) | 2 | Love et al. 2012 | |
|
| 167 | +| [IGLL5](IGLL5) | 2, aSHM | Russler-Germain et al. 2023; Panea et al. 2019; Desch et al. 2020 | |
|
| 168 | +| [IKZF3](IKZF3) | 2, aSHM | Morin et al. 2013; Panea et al. 2019 | |
|
| 169 | +| [IRF8](IRF8) | 2, aSHM | Mottok et al. 2019; Morin et al. 2011; Panea et al. 2019 | |
|
| 170 | +| [ITPR3](ITPR3) | 2 | Tiacci et al. 2018; Love et al. 2012 | |
|
| 171 | +| [KANK2](KANK2) | 2 | Schmitz et al. 2012 | |
|
| 172 | +| [KCNK10](KCNK10) | 2 | Panea et al. 2019 | |
|
| 173 | +| [KIFC3](KIFC3) | 2 | Love et al. 2012 | |
|
| 174 | +| [KLHL26](KLHL26) | 2 | Burkhardt et al. 2022 | |
|
| 175 | +| [KLHL6](KLHL6) | 2, aSHM | Ganapathi et al. 2016; Panea et al. 2019; Morin et al. 2011 | |
|
| 176 | +| [KMT2C](KMT2C) | 2 | Zhang et al. 2013; Zhou et al. 2019; Sarkozy et al. 2021; Zhang et al. 2014 | |
|
| 177 | +| [LTB](LTB) | 2, aSHM | Panea et al. 2019; Chapuy et al. 2018; Desch et al. 2020 | |
|
| 178 | +| [MAP3K6](MAP3K6) | 2 | Love et al. 2012 | |
|
| 179 | +| [MCL1](MCL1) | 2 | Reddy et al. 2017; Duns et al. 2021; Panea et al. 2019 | |
|
| 180 | +| [MIR142](MIR142) | 2, aSHM | Grande et al. 2019; Kwanhian et al. 2012 | |
|
| 181 | +| [MKI67](MKI67) | 2 | Russler-Germain et al. 2023; Schmitz et al. 2012 | |
|
| 182 | +| [MME](MME) | 2 | Panea et al. 2019 | |
|
| 183 | +| [MTOR](MTOR) | 2 | Panea et al. 2019; Zhang et al. 2013 | |
|
| 184 | +| [MYH10](MYH10) | 2 | Love et al. 2012 | |
|
| 185 | +| [MYO18A](MYO18A) | 2 | Schmitz et al. 2012 | |
|
| 186 | +| [NBEAL1](NBEAL1) | 2 | Love et al. 2012 | |
|
| 187 | +| [NCOR2](NCOR2) | 2 | Spina et al. 2016; Sarkozy et al. 2021; Schmitz et al. 2012 | |
|
| 188 | +| [NOA1](NOA1) | 2 | Burkhardt et al. 2022 | |
|
| 189 | +| [NOTCH1](NOTCH1) | 2 | Love et al. 2012; Laura Pasqualucci, Trifonov, et al. 2011; Beà et al. 2013; Rossi et al. 2012 | |
|
| 190 | +| [NOTCH2](NOTCH2) | 2 | Rossi et al. 2012; Panea et al. 2019; Trøen et al. 2008; Beà et al. 2013 | |
|
| 191 | +| [NRXN2](NRXN2) | 2 | Love et al. 2012 | |
|
| 192 | +| [P2RY2](P2RY2) | 2 | Love et al. 2012 | |
|
| 193 | +| [PABPC4L](PABPC4L) | 2 | Panea et al. 2019 | |
|
| 194 | +| [PC](PC) | 2 | Love et al. 2012 | |
|
| 195 | +| [PCBP1](PCBP1) | 2 | Schmitz et al. 2012 | |
|
| 196 | +| [PCDHA11](PCDHA11) | 2 | Panea et al. 2019 | |
|
| 197 | +| [PDCD11](PDCD11) | 2 | Schmitz et al. 2012 | |
|
| 198 | +| [PDZRN3](PDZRN3) | 2 | Panea et al. 2019 | |
|
| 199 | +| [PIK3R1](PIK3R1) | 2 | Zhang et al. 2013; Panea et al. 2019 | |
|
| 200 | +| [PIM1](PIM1) | 2, aSHM | Burkhardt et al. 2022; Duns et al. 2021; L. Pasqualucci et al. 2001 | |
|
| 201 | +| [PLCG2](PLCG2) | 2 | Panea et al. 2019 | |
|
| 202 | +| [POLRMT](POLRMT) | 2 | Love et al. 2012 | |
|
| 203 | +| [POR](POR) | 2 | Love et al. 2012 | |
|
| 204 | +| [PPP6R2](PPP6R2) | 2 | Burkhardt et al. 2022 | |
|
| 205 | +| [PREX1](PREX1) | 2 | Burkhardt et al. 2022 | |
|
| 206 | +| [PRSS22](PRSS22) | 2 | Love et al. 2012 | |
|
| 207 | +| [PTPRN](PTPRN) | 2 | Love et al. 2012 | |
|
| 208 | +| [PXDNL](PXDNL) | 2 | Panea et al. 2019 | |
|
| 209 | +| [RAC2](RAC2) | 2 | Hübschmann et al. 2021; Panea et al. 2019 | |
|
| 210 | +| [RANBP6](RANBP6) | 2 | Love et al. 2012 | |
|
| 211 | +| [RBP3](RBP3) | 2 | Love et al. 2012 | |
|
| 212 | +| [RET](RET) | 2 | Love et al. 2012 | |
|
| 213 | +| [REV3L](REV3L) | 2 | Burkhardt et al. 2022 | |
|
| 214 | +| [RNF144B](RNF144B) | 2 | Panea et al. 2019 | |
|
| 215 | +| [RPL10](RPL10) | 2 | Burkhardt et al. 2022 | |
|
| 216 | +| [S1PR2](S1PR2) | 2, aSHM | Morin et al. 2011; Muppidi et al. 2014 | |
|
| 217 | +| [SAL3](SAL3) | 2 | Burkhardt et al. 2022 | |
|
| 218 | +| [SALL3](SALL3) | 2 | Love et al. 2012; Zhang et al. 2014 | |
|
| 219 | +| [SAPS2](SAPS2) | 2 | Love et al. 2012 | |
|
| 220 | +| [SBF1](SBF1) | 2 | Love et al. 2012 | |
|
| 221 | +| [SF3B1](SF3B1) | 2 | Love et al. 2012 | |
|
| 222 | +| [SHANK1](SHANK1) | 2 | Love et al. 2012 | |
|
| 223 | +| [SLC29A2](SLC29A2) | 2 | Love et al. 2012 | |
|
| 224 | +| [SNTB2](SNTB2) | 2 | Panea et al. 2019 | |
|
| 225 | +| [SP3](SP3) | 2 | Panea et al. 2019 | |
|
| 226 | +| [SYNCRIP](SYNCRIP) | 2 | Panea et al. 2019 | |
|
| 227 | +| [SYNGAP1](SYNGAP1) | 2 | Love et al. 2012 | |
|
| 228 | +| [TBC1D9B](TBC1D9B) | 2 | Love et al. 2012 | |
|
| 229 | +| [TET2](TET2) | 2 | Albuquerque et al. 2017; Panea et al. 2019 | |
|
| 230 | +| [TIGD6](TIGD6) | 2 | Love et al. 2012 | |
|
| 231 | +| [TOP2A](TOP2A) | 2 | Schmitz et al. 2012 | |
|
| 232 | +| [TPST2](TPST2) | 2 | Love et al. 2012 | |
|
| 233 | +| [TTN](TTN) | 2 | Burkhardt et al. 2022 | |
|
| 234 | +| [VWA7](VWA7) | 2 | Burkhardt et al. 2022 | |
|
| 235 | +| [WDR7](WDR7) | 2 | Panea et al. 2019 | |
|
| 236 | +| [WDR90](WDR90) | 2 | Schmitz et al. 2012 | |
|
| 237 | +| [WHAMM](WHAMM) | 2 | Schmitz et al. 2012 | |
|
| 238 | +| [WNK2](WNK2) | 2 | Panea et al. 2019 | |
|
| 239 | +| [YY1AP1](YY1AP1) | 2 | Schmitz et al. 2012 | |
|
| 240 | +| [ZAN](ZAN) | 2 | Burkhardt et al. 2022 | |
|
| 241 | +| [ZBTB7A](ZBTB7A) | 2 | Burkhardt et al. 2022; Reddy et al. 2017 | |
|
| 242 | +| [ZFP36L1](ZFP36L1) | 2, aSHM | Morin et al. 2011; Reichel et al. 2015; Panea et al. 2019 | |
|
| 243 | +| [ZNF229](ZNF229) | 2 | Love et al. 2012 | |
|
| 244 | +| [ZNF85](ZNF85) | 2 | Burkhardt et al. 2022 | |
|
| 245 | 245 | |
| 246 | 246 | # References |
| 247 | 247 | |
| ... | ... | @@ -317,6 +317,43 @@ Pathogenic Mechanisms and Outcomes.” *Nature Medicine* 24 5: 679–90. |
| 317 | 317 | |
| 318 | 318 | </div> |
| 319 | 319 | |
| 320 | +<div id="ref-deschGenotypingCirculatingTumor2020" class="csl-entry"> |
|
| 321 | + |
|
| 322 | +Desch, Ann-Kathrin, Kristin Hartung, Ante Botzen, Alexander Brobeil, |
|
| 323 | +Mathias Rummel, Lars Kurch, Thomas Georgi, et al. 2020. “Genotyping |
|
| 324 | +Circulating Tumor DNA of Pediatric Hodgkin Lymphoma.” *Leukemia* 34 1: |
|
| 325 | +151–66. <https://doi.org/10.1038/s41375-019-0541-6>. |
|
| 326 | + |
|
| 327 | +</div> |
|
| 328 | + |
|
| 329 | +<div id="ref-dunsCharacterizationDLBCLPMBL2021b" class="csl-entry"> |
|
| 330 | + |
|
| 331 | +Duns, Gerben, Elena Viganò, Daisuke Ennishi, Clementine Sarkozy, Stacy |
|
| 332 | +S. Hung, Elizabeth Chavez, Katsuyoshi Takata, et al. 2021. |
|
| 333 | +“Characterization of DLBCL with a PMBL Gene Expression Signature.” |
|
| 334 | +*Blood* 138 2: 136–48. <https://doi.org/10.1182/blood.2020007683>. |
|
| 335 | + |
|
| 336 | +</div> |
|
| 337 | + |
|
| 338 | +<div id="ref-ganapathiGeneticLandscapeDural2016" class="csl-entry"> |
|
| 339 | + |
|
| 340 | +Ganapathi, Karthik A., Vaidehi Jobanputra, Fabio Iwamoto, Preti Jain, |
|
| 341 | +Jinli Chen, Luciano Cascione, Odelia Nahum, et al. 2016. “The Genetic |
|
| 342 | +Landscape of Dural Marginal Zone Lymphomas.” *Oncotarget* 7 28: |
|
| 343 | +43052–61. <https://doi.org/10.18632/oncotarget.9678>. |
|
| 344 | + |
|
| 345 | +</div> |
|
| 346 | + |
|
| 347 | +<div id="ref-gomezUltraDeepSequencingReveals2023" class="csl-entry"> |
|
| 348 | + |
|
| 349 | +Gomez, Felicia, Bryan Fisk, Joshua F. McMichael, Matthew Mosior, |
|
| 350 | +Jennifer A. Foltz, Zachary L. Skidmore, Eric J. Duncavage, et al. 2023. |
|
| 351 | +“Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical |
|
| 352 | +Hodgkin Lymphoma.” *Cancer Research Communications* 3 11: 2312–30. |
|
| 353 | +<https://doi.org/10.1158/2767-9764.CRC-23-0140>. |
|
| 354 | + |
|
| 355 | +</div> |
|
| 356 | + |
|
| 320 | 357 | <div id="ref-grandeGenomewideDiscoverySomatic2019" class="csl-entry"> |
| 321 | 358 | |
| 322 | 359 | Grande, Bruno M., Daniela S. Gerhard, Aixiang Jiang, Nicholas B. Griner, |
| ... | ... | @@ -339,6 +376,17 @@ Germinal Center Derived <span class="nocase">B-cell</span> Lymphomas.” |
| 339 | 376 | |
| 340 | 377 | </div> |
| 341 | 378 | |
| 379 | +<div id="ref-jalladesExomeSequencingIdentifies2017" class="csl-entry"> |
|
| 380 | + |
|
| 381 | +Jallades, Laurent, Lucile Baseggio, Pierre Sujobert, Sarah Huet, Kaddour |
|
| 382 | +Chabane, Evelyne Callet-Bauchu, Aurélie Verney, et al. 2017. “Exome |
|
| 383 | +Sequencing Identifies Recurrent BCOR Alterations and the Absence of |
|
| 384 | +KLF2, TNFAIP3 and MYD88 Mutations in Splenic Diffuse Red Pulp Small |
|
| 385 | +<span class="nocase">B-cell</span> Lymphoma.” *Haematologica* 102 10: |
|
| 386 | +1758–66. <https://doi.org/10.3324/haematol.2016.160192>. |
|
| 387 | + |
|
| 388 | +</div> |
|
| 389 | + |
|
| 342 | 390 | <div id="ref-johnstonCmycHypermutationBurkitt1992" class="csl-entry"> |
| 343 | 391 | |
| 344 | 392 | Johnston, J. M., and W. L. Carroll. 1992. “C-Myc Hypermutation in |
| ... | ... | @@ -440,6 +488,16 @@ Lymphoma Using Whole-Genome Sequencing.” *Blood* 122 7: 1256–65. |
| 440 | 488 | |
| 441 | 489 | </div> |
| 442 | 490 | |
| 491 | +<div id="ref-mottokIntegrativeGenomicAnalysis2019b" class="csl-entry"> |
|
| 492 | + |
|
| 493 | +Mottok, Anja, Stacy S. Hung, Elizabeth A. Chavez, Bruce Woolcock, Adèle |
|
| 494 | +Telenius, Lauren C. Chong, Barbara Meissner, et al. 2019. “Integrative |
|
| 495 | +Genomic Analysis Identifies Key Pathogenic Mechanisms in Primary |
|
| 496 | +Mediastinal Large <span class="nocase">B-cell</span> Lymphoma.” *Blood* |
|
| 497 | +134 10: 802–13. <https://doi.org/10.1182/blood.2019001126>. |
|
| 498 | + |
|
| 499 | +</div> |
|
| 500 | + |
|
| 443 | 501 | <div id="ref-muppidiLossSignalingGa132014b" class="csl-entry"> |
| 444 | 502 | |
| 445 | 503 | Muppidi, J., R. Schmitz, Jesse A. Green, Jesse A. Green, Wenming Xiao, |
| ... | ... | @@ -467,6 +525,16 @@ Lymphoma Subtypes.” *Blood*. <https://doi.org/10.1182/blood.2019001880>. |
| 467 | 525 | |
| 468 | 526 | </div> |
| 469 | 527 | |
| 528 | +<div id="ref-parryWholeExomeSequencing2013" class="csl-entry"> |
|
| 529 | + |
|
| 530 | +Parry, Marina, Matthew J. J. Rose-Zerilli, Jane Gibson, Sarah Ennis, |
|
| 531 | +Renata Walewska, Jade Forster, Helen Parker, et al. 2013. “Whole Exome |
|
| 532 | +Sequencing Identifies Novel Recurrently Mutated Genes in Patients with |
|
| 533 | +Splenic Marginal Zone Lymphoma.” *PloS One* 8 12: e83244. |
|
| 534 | +<https://doi.org/10.1371/journal.pone.0083244>. |
|
| 535 | + |
|
| 536 | +</div> |
|
| 537 | + |
|
| 470 | 538 | <div id="ref-pasqualucciInactivatingMutationsAcetyltransferase2011a" |
| 471 | 539 | class="csl-entry"> |
| 472 | 540 | |
| ... | ... | @@ -508,6 +576,16 @@ and Functional Drivers of Diffuse Large B Cell Lymphoma.” *Cell* 171 |
| 508 | 576 | |
| 509 | 577 | </div> |
| 510 | 578 | |
| 579 | +<div id="ref-reichelFlowSortingExome2015a" class="csl-entry"> |
|
| 580 | + |
|
| 581 | +Reichel, Jonathan, Amy Chadburn, Paul G. Rubinstein, Lisa Giulino-Roth, |
|
| 582 | +Wayne Tam, Yifang Liu, Rafael Gaiolla, et al. 2015. “Flow Sorting and |
|
| 583 | +Exome Sequencing Reveal the Oncogenome of Primary Hodgkin and |
|
| 584 | +Reed-Sternberg Cells.” *Blood* 125 7: 1061–72. |
|
| 585 | +<https://doi.org/10.1182/blood-2014-11-610436>. |
|
| 586 | + |
|
| 587 | +</div> |
|
| 588 | + |
|
| 511 | 589 | <div id="ref-richterRecurrentMutationID32012a" class="csl-entry"> |
| 512 | 590 | |
| 513 | 591 | Richter, Julia, Matthias Schlesner, Steve Hoffmann, Markus Kreuz, Ellen |
| ... | ... | @@ -518,6 +596,17 @@ Genome, Exome and Transcriptome Sequencing.” *Nature Genetics* 44 12: |
| 518 | 596 | |
| 519 | 597 | </div> |
| 520 | 598 | |
| 599 | +<div id="ref-rossiCodingGenomeSplenic2012c" class="csl-entry"> |
|
| 600 | + |
|
| 601 | +Rossi, Davide, Vladimir Trifonov, Marco Fangazio, Alessio Bruscaggin, |
|
| 602 | +Silvia Rasi, Valeria Spina, Sara Monti, et al. 2012. “The Coding Genome |
|
| 603 | +of Splenic Marginal Zone Lymphoma: Activation of NOTCH2 and Other |
|
| 604 | +Pathways Regulating Marginal Zone Development.” *The Journal of |
|
| 605 | +Experimental Medicine* 209 9: 1537–51. |
|
| 606 | +<https://doi.org/10.1084/jem.20120904>. |
|
| 607 | + |
|
| 608 | +</div> |
|
| 609 | + |
|
| 521 | 610 | <div id="ref-russler-germainMutationsAssociatedProgression2023b" |
| 522 | 611 | class="csl-entry"> |
| 523 | 612 | |
| ... | ... | @@ -530,6 +619,15 @@ Advances* 7: 5524–39. |
| 530 | 619 | |
| 531 | 620 | </div> |
| 532 | 621 | |
| 622 | +<div id="ref-sarkozyMutationalLandscapeGray2021a" class="csl-entry"> |
|
| 623 | + |
|
| 624 | +Sarkozy, Clémentine, Stacy S. Hung, Elizabeth A. Chavez, Gerben Duns, |
|
| 625 | +Katsuyoshi Takata, Lauren C. Chong, Tomohiro Aoki, et al. 2021. |
|
| 626 | +“Mutational Landscape of Gray Zone Lymphoma.” *Blood* 137 13: 1765–76. |
|
| 627 | +<https://doi.org/10.1182/blood.2020007507>. |
|
| 628 | + |
|
| 629 | +</div> |
|
| 630 | + |
|
| 533 | 631 | <div id="ref-schmitzGeneticsPathogenesisDiffuse2018a" class="csl-entry"> |
| 534 | 632 | |
| 535 | 633 | Schmitz, Roland, George W. Wright, Da Wei Huang, Calvin A. Johnson, |
| ... | ... | @@ -550,6 +648,15 @@ Genomics.” *Nature* 490 7418: 116–20. |
| 550 | 648 | |
| 551 | 649 | </div> |
| 552 | 650 | |
| 651 | +<div id="ref-spinaGeneticsNodalMarginal2016b" class="csl-entry"> |
|
| 652 | + |
|
| 653 | +Spina, Valeria, Hossein Khiabanian, Monica Messina, Sara Monti, Luciano |
|
| 654 | +Cascione, Alessio Bruscaggin, Elisa Spaccarotella, et al. 2016. “The |
|
| 655 | +Genetics of Nodal Marginal Zone Lymphoma.” *Blood* 128 10: 1362–73. |
|
| 656 | +<https://doi.org/10.1182/blood-2016-02-696757>. |
|
| 657 | + |
|
| 658 | +</div> |
|
| 659 | + |
|
| 553 | 660 | <div id="ref-tanakaFrequentIncidenceSomatic1992" class="csl-entry"> |
| 554 | 661 | |
| 555 | 662 | Tanaka, S., D. C. Louie, J. A. Kant, and J. C. Reed. 1992. “Frequent |
| ... | ... | @@ -568,6 +675,16 @@ Lymphoma.” *Blood* 141 8: 904–16. |
| 568 | 675 | |
| 569 | 676 | </div> |
| 570 | 677 | |
| 678 | +<div id="ref-tiacciPervasiveMutationsJAKSTAT2018b" class="csl-entry"> |
|
| 679 | + |
|
| 680 | +Tiacci, Enrico, Erik Ladewig, Gianluca Schiavoni, Alex Penson, |
|
| 681 | +Elisabetta Fortini, Valentina Pettirossi, Yuchun Wang, et al. 2018. |
|
| 682 | +“Pervasive Mutations of JAK-STAT Pathway Genes in Classical Hodgkin |
|
| 683 | +Lymphoma.” *Blood* 131 22: 2454–65. |
|
| 684 | +<https://doi.org/10.1182/blood-2017-11-814913>. |
|
| 685 | + |
|
| 686 | +</div> |
|
| 687 | + |
|
| 571 | 688 | <div id="ref-tiacciBRAFMutationsHairycell2011a" class="csl-entry"> |
| 572 | 689 | |
| 573 | 690 | Tiacci, Enrico, Vladimir Trifonov, Gianluca Schiavoni, Antony Holmes, |
| ... | ... | @@ -586,6 +703,16 @@ Mutations in Marginal Zone Lymphoma.” *Haematologica* 93 7: 1107–9. |
| 586 | 703 | |
| 587 | 704 | </div> |
| 588 | 705 | |
| 706 | +<div id="ref-wienandGenomicAnalysesFlowsorted2019b" class="csl-entry"> |
|
| 707 | + |
|
| 708 | +Wienand, Kirsty, Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, David |
|
| 709 | +Wu, Jaegil Kim, Atanas Kamburov, et al. 2019. “Genomic Analyses of |
|
| 710 | +Flow-Sorted Hodgkin Reed-Sternberg Cells Reveal Complementary Mechanisms |
|
| 711 | +of Immune Evasion.” *Blood Advances* 3 23: 4065–80. |
|
| 712 | +<https://doi.org/10.1182/bloodadvances.2019001012>. |
|
| 713 | + |
|
| 714 | +</div> |
|
| 715 | + |
|
| 589 | 716 | <div id="ref-wildaInactivationARFMDM2p53Pathway2004" class="csl-entry"> |
| 590 | 717 | |
| 591 | 718 | Wilda, M., J. Bruch, L. Harder, D. Rawer, A. Reiter, A. Borkhardt, and |
| ... | ... | @@ -606,6 +733,17 @@ Recurrent CARD11 Mutations.” *Oncotarget* 7 25: 38180–90. |
| 606 | 733 | |
| 607 | 734 | </div> |
| 608 | 735 | |
| 736 | +<div id="ref-yanBCRTLRSignaling2012a" class="csl-entry"> |
|
| 737 | + |
|
| 738 | +Yan, Qingguo, Yuanxue Huang, A. James Watkins, Sylvia Kocialkowski, |
|
| 739 | +Naiyan Zeng, Rifat A. Hamoudi, Peter G. Isaacson, Laurence de Leval, |
|
| 740 | +Andrew Wotherspoon, and Ming-Qing Du. 2012. “BCR and TLR Signaling |
|
| 741 | +Pathways Are Recurrently Targeted by Genetic Changes in Splenic Marginal |
|
| 742 | +Zone Lymphomas.” *Haematologica* 97 4: 595–98. |
|
| 743 | +<https://doi.org/10.3324/haematol.2011.054080>. |
|
| 744 | + |
|
| 745 | +</div> |
|
| 746 | + |
|
| 609 | 747 | <div id="ref-zhangGeneticHeterogeneityDiffuse2013" class="csl-entry"> |
| 610 | 748 | |
| 611 | 749 | Zhang, Jenny, Vladimir Grubor, Cassandra L Love, Anjishnu Banerjee, |
CD70.md
| ... | ... | @@ -64,4 +64,4 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C |
| 64 | 64 |  |
| 65 | 65 | <!-- ORIGIN: morinFrequentMutationHistonemodifying2011 --> |
| 66 | 66 | <!-- DLBCL: morinFrequentMutationHistonemodifying2011 --> |
| 67 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 67 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
CD83.md
| ... | ... | @@ -74,7 +74,7 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C |
| 74 | 74 | 4. *Russler-Germain DA, Krysiak K, Ramirez C, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen AF, Mehta-Shah N, Kahl BS, Bartlett NL, Alderuccio JP, Lossos IS, Ondrejka SL, Hsi ED, Martin P, Leonard JP, Griffith M, Griffith OL, Fehniger TA. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Adv. 2023 Sep 26;7(18):5524-5539. doi: 10.1182/bloodadvances.2023010779. PMID: 37493986; PMCID: PMC10514406.* |
| 75 | 75 | <!-- ORIGIN: morinMutationalStructuralAnalysis2013 --> |
| 76 | 76 | <!-- BL: paneaWholeGenomeLandscape2019 --> |
| 77 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 77 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 78 | 78 | <!-- BL: paneaWholeGenomeLandscape2019 --> |
| 79 | 79 | <!-- DLBCL: morinMutationalStructuralAnalysis2013 --> |
| 80 | 80 | <!-- PMBL: dunsCharacterizationDLBCLPMBL2021b --> |
CILP.md
| ... | ... | @@ -42,6 +42,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/C |
| 42 | 42 | ## CILP Expression |
| 43 | 43 |  |
| 44 | 44 | <!-- ORIGIN: russler-germainMutationsAssociatedProgression2023a --> |
| 45 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 45 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 46 | 46 | ## References |
| 47 | 47 | 1. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |
GBP7.md
| ... | ... | @@ -41,6 +41,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/G |
| 41 | 41 | ## GBP7 Expression |
| 42 | 42 |  |
| 43 | 43 | <!-- ORIGIN: russler-germainMutationsAssociatedProgression2023a --> |
| 44 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 44 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 45 | 45 | ## References |
| 46 | 46 | 1. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |
GRM6.md
| ... | ... | @@ -41,6 +41,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/G |
| 41 | 41 | ## GRM6 Expression |
| 42 | 42 |  |
| 43 | 43 | <!-- ORIGIN: russler-germainMutationsAssociatedProgression2023a --> |
| 44 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 44 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 45 | 45 | ## References |
| 46 | 46 | 1. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |
IGLL5.md
| ... | ... | @@ -65,5 +65,5 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/I |
| 65 | 65 | <!-- PMBL: deschGenotypingCirculatingTumor2020 --> |
| 66 | 66 | <!-- ORIGIN: deschGenotypingCirculatingTumor2020 --> |
| 67 | 67 | <!-- BL: paneaWholeGenomeLandscape2019 --> |
| 68 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 68 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 69 | 69 | <!-- BL: paneaWholeGenomeLandscape2019 --> |
KIR3DL1.md
| ... | ... | @@ -41,6 +41,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/K |
| 41 | 41 | ## KIR3DL1 Expression |
| 42 | 42 |  |
| 43 | 43 | <!-- ORIGIN: russler-germainMutationsAssociatedProgression2023a --> |
| 44 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 44 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 45 | 45 | ## References |
| 46 | 46 | 1. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |
MAGEC1.md
| ... | ... | @@ -50,6 +50,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/M |
| 50 | 50 | ## MAGEC1 Expression |
| 51 | 51 |  |
| 52 | 52 | <!-- ORIGIN: russler-germainMutationsAssociatedProgression2023a --> |
| 53 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 53 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 54 | 54 | ## References |
| 55 | 55 | 1. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |
MAP7D1.md
| ... | ... | @@ -41,6 +41,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/M |
| 41 | 41 | ## MAP7D1 Expression |
| 42 | 42 |  |
| 43 | 43 | <!-- ORIGIN: russler-germainMutationsAssociatedProgression2023a --> |
| 44 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 44 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 45 | 45 | ## References |
| 46 | 46 | 1. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |
MCL_genes.md
| ... | ... | @@ -34,84 +34,84 @@ WGS/exome, Bea 2013, 27 |
| 34 | 34 | |
| 35 | 35 | ### *23 total* |
| 36 | 36 | |
| 37 | -| Gene | Tier | Relevant references | |
|
| 38 | -|:------------------:|:------------:|:---------------------------------------------------------------------------------| |
|
| 39 | -| [ATM](ATM) | 1 | Reddy et al. 2017; Beà et al. 2013 | |
|
| 40 | -| [BIRC3](BIRC3) | 1 | Arthur et al. 2018; Beà et al. 2013 | |
|
| 41 | -| [CARD11](CARD11) | 1 | Lenz et al. 2008; Wu et al. 2016; Morin et al. 2011; Panea et al. 2019 | |
|
| 42 | -| [CCND1](CCND1) | 1, aSHM | Beà et al. 2013 | |
|
| 43 | -| [DAZAP1](DAZAP1) | 1 | Pararajalingam et al. 2020 | |
|
| 44 | -| [EWSR1](EWSR1) | 1 | Pararajalingam et al. 2020 | |
|
| 45 | -| [HNRNPH1](HNRNPH1) | 1, noncoding | Pararajalingam et al. 2020 | |
|
| 46 | -| [KMT2D](KMT2D) | 1 | Grande et al. 2019; Beà et al. 2013; Morin et al. 2011 | |
|
| 47 | -| [MEF2B](MEF2B) | 1 | Beà et al. 2013; Morin et al. 2011 | |
|
| 48 | -| [NFKBIE](NFKBIE) | 1 | Pararajalingam et al. 2020; Morin et al. 2016 | |
|
| 49 | -| [NOTCH1](NOTCH1) | 1 | Love et al. 2012; Pasqualucci et al. 2011; Beà et al. 2013 | |
|
| 50 | -| [NOTCH2](NOTCH2) | 1 | Trøen et al. 2008; Beà et al. 2013; Panea et al. 2019 | |
|
| 51 | -| [NSD2](NSD2) | 1 | Beà et al. 2013 | |
|
| 52 | -| [POT1](POT1) | 1 | Zhang et al. 2014 | |
|
| 53 | -| [RB1](RB1) | 1 | Zhang et al. 2014; Morin et al. 2013 | |
|
| 54 | -| [S1PR1](S1PR1) | 1 | Pararajalingam et al. 2020 | |
|
| 55 | -| [SMARCA4](SMARCA4) | 1 | Krysiak et al. 2017; Nadeu et al. 2020; Zhang et al. 2013; Richter et al. 2012 | |
|
| 56 | -| [SP140](SP140) | 1 | Beà et al. 2013 | |
|
| 57 | -| [SYNE1](SYNE1) | 1 | Nadeu et al. 2020 | |
|
| 58 | -| [TERT](TERT) | 1, noncoding | Nadeu et al. 2020 | |
|
| 59 | -| [TLR2](TLR2) | 1 | Beà et al. 2013; Chapuy et al. 2018 | |
|
| 60 | -| [TP53](TP53) | 1 | Beà et al. 2013; Wilda et al. 2004; Morin et al. 2011 | |
|
| 61 | -| [UBR5](UBR5) | 1 | Pararajalingam et al. 2020; Zhang et al. 2013 | |
|
| 37 | +| Gene | Tier | Relevant references | |
|
| 38 | +|:------------------:|:------------:|:-----------------------------------------------------------------------------------------------| |
|
| 39 | +| [ATM](ATM) | 1 | Beà et al. 2013; Braggio et al. 2012; Reddy et al. 2017 | |
|
| 40 | +| [BIRC3](BIRC3) | 1 | Duns et al. 2021; Rossi et al. 2011; Arthur et al. 2018; Beà et al. 2013 | |
|
| 41 | +| [CARD11](CARD11) | 1 | Wu et al. 2016; Panea et al. 2019; Morin et al. 2011; Yan et al. 2012; Lenz et al. 2008 | |
|
| 42 | +| [CCND1](CCND1) | 1, aSHM | Beà et al. 2013 | |
|
| 43 | +| [DAZAP1](DAZAP1) | 1 | Pararajalingam et al. 2020 | |
|
| 44 | +| [EWSR1](EWSR1) | 1 | Pararajalingam et al. 2020 | |
|
| 45 | +| [HNRNPH1](HNRNPH1) | 1, noncoding | Pararajalingam et al. 2020 | |
|
| 46 | +| [KMT2D](KMT2D) | 1 | Grande et al. 2019; Beà et al. 2013; Morin et al. 2011; Desch et al. 2020; Rossi et al. 2012 | |
|
| 47 | +| [MEF2B](MEF2B) | 1 | Beà et al. 2013; Morin et al. 2011 | |
|
| 48 | +| [NFKBIE](NFKBIE) | 1 | Mansouri et al. 2016; Pararajalingam et al. 2020; Morin et al. 2016 | |
|
| 49 | +| [NOTCH1](NOTCH1) | 1 | Rossi et al. 2012; Love et al. 2012; Pasqualucci et al. 2011; Beà et al. 2013 | |
|
| 50 | +| [NOTCH2](NOTCH2) | 1 | Trøen et al. 2008; Beà et al. 2013; Rossi et al. 2012; Panea et al. 2019 | |
|
| 51 | +| [NSD2](NSD2) | 1 | Beà et al. 2013 | |
|
| 52 | +| [POT1](POT1) | 1 | Zhang et al. 2014 | |
|
| 53 | +| [RB1](RB1) | 1 | Zhang et al. 2014; Morin et al. 2013 | |
|
| 54 | +| [S1PR1](S1PR1) | 1 | Pararajalingam et al. 2020 | |
|
| 55 | +| [SMARCA4](SMARCA4) | 1 | Nadeu et al. 2020; Zhang et al. 2013; Krysiak et al. 2017; Richter et al. 2012 | |
|
| 56 | +| [SP140](SP140) | 1 | Beà et al. 2013 | |
|
| 57 | +| [SYNE1](SYNE1) | 1 | Nadeu et al. 2020 | |
|
| 58 | +| [TERT](TERT) | 1, noncoding | Nadeu et al. 2020 | |
|
| 59 | +| [TLR2](TLR2) | 1 | Chapuy et al. 2018; Beà et al. 2013 | |
|
| 60 | +| [TP53](TP53) | 1 | Rossi et al. 2012; Wilda et al. 2004; Morin et al. 2011; Tiacci et al. 2018; Beà et al. 2013 | |
|
| 61 | +| [UBR5](UBR5) | 1 | Pararajalingam et al. 2020; Zhang et al. 2013 | |
|
| 62 | 62 | |
| 63 | 63 | ## Tier 2 MCL genes |
| 64 | 64 | |
| 65 | 65 | ### *46 total* |
| 66 | 66 | |
| 67 | -| Gene | Tier | Relevant references | |
|
| 68 | -|:--------------------:|:----:|:---------------------------------------------------------| |
|
| 69 | -| [ABCA3](ABCA3) | 2 | Beà et al. 2013 | |
|
| 70 | -| [ABCC9](ABCC9) | 2 | Beà et al. 2013 | |
|
| 71 | -| [ANK2](ANK2) | 2 | Zhang et al. 2014 | |
|
| 72 | -| [ARID1B](ARID1B) | 2 | Reddy et al. 2017 | |
|
| 73 | -| [ATP11C](ATP11C) | 2 | Zhang et al. 2014 | |
|
| 74 | -| [B2M](B2M) | 2 | Pararajalingam et al. 2020; Morin et al. 2011 | |
|
| 75 | -| [BCOR](BCOR) | 2 | Nadeu et al. 2020 | |
|
| 76 | -| [CDH8](CDH8) | 2 | Zhang et al. 2014 | |
|
| 77 | -| [CHMP4C](CHMP4C) | 2 | Beà et al. 2013 | |
|
| 78 | -| [COL11A1](COL11A1) | 2 | Zhang et al. 2014 | |
|
| 79 | -| [COL16A1](COL16A1) | 2 | Zhang et al. 2014 | |
|
| 80 | -| [CRYBG3](CRYBG3) | 2 | Beà et al. 2013 | |
|
| 81 | -| [CTNNA2](CTNNA2) | 2 | Zhang et al. 2014 | |
|
| 82 | -| [DCP1B](DCP1B) | 2 | Beà et al. 2013 | |
|
| 83 | -| [DHDH](DHDH) | 2 | Zhang et al. 2014 | |
|
| 84 | -| [DLC1](DLC1) | 2 | Zhang et al. 2014 | |
|
| 85 | -| [DLGAP2](DLGAP2) | 2 | Beà et al. 2013 | |
|
| 86 | -| [DNAJC6](DNAJC6) | 2 | Beà et al. 2013 | |
|
| 87 | -| [EIF2AK4](EIF2AK4) | 2 | Zhang et al. 2014 | |
|
| 88 | -| [ESX1](ESX1) | 2 | Zhang et al. 2014 | |
|
| 89 | -| [FAT4](FAT4) | 2 | Zhang et al. 2014; Morin et al. 2013 | |
|
| 90 | -| [GRIN2A](GRIN2A) | 2 | Zhang et al. 2014 | |
|
| 91 | -| [HEPH](HEPH) | 2 | Zhang et al. 2014 | |
|
| 92 | -| [KCNC2](KCNC2) | 2 | Beà et al. 2013 | |
|
| 93 | -| [KIAA1671](KIAA1671) | 2 | Beà et al. 2013 | |
|
| 94 | -| [KMT2C](KMT2C) | 2 | Zhang et al. 2014; Zhang et al. 2013; Zhou et al. 2019 | |
|
| 95 | -| [LUZP4](LUZP4) | 2 | Beà et al. 2013 | |
|
| 96 | -| [MRGPRF](MRGPRF) | 2 | Zhang et al. 2014 | |
|
| 97 | -| [NIN](NIN) | 2 | Zhang et al. 2014 | |
|
| 98 | -| [OGDHL](OGDHL) | 2 | Zhang et al. 2014 | |
|
| 99 | -| [PCDHB2](PCDHB2) | 2 | Zhang et al. 2014 | |
|
| 100 | -| [PCSK2](PCSK2) | 2 | Beà et al. 2013 | |
|
| 101 | -| [PDLIM3](PDLIM3) | 2 | Beà et al. 2013 | |
|
| 102 | -| [PLXNB3](PLXNB3) | 2 | Zhang et al. 2014 | |
|
| 103 | -| [RGS4](RGS4) | 2 | Beà et al. 2013 | |
|
| 104 | -| [ROBO2](ROBO2) | 2 | Zhang et al. 2014 | |
|
| 105 | -| [SALL3](SALL3) | 2 | Zhang et al. 2014; Love et al. 2012 | |
|
| 106 | -| [SI](SI) | 2 | Zhang et al. 2014 | |
|
| 107 | -| [SLC17A6](SLC17A6) | 2 | Beà et al. 2013 | |
|
| 108 | -| [SMARCB1](SMARCB1) | 2 | Nadeu et al. 2020 | |
|
| 109 | -| [SMC1A](SMC1A) | 2 | Zhang et al. 2014 | |
|
| 110 | -| [TBC1D26](TBC1D26) | 2 | Zhang et al. 2014 | |
|
| 111 | -| [TNRC6B](TNRC6B) | 2 | Beà et al. 2013 | |
|
| 112 | -| [TRPM6](TRPM6) | 2 | Beà et al. 2013 | |
|
| 113 | -| [ZNF117](ZNF117) | 2 | Zhang et al. 2014 | |
|
| 114 | -| [ZNF296](ZNF296) | 2 | Zhang et al. 2014 | |
|
| 67 | +| Gene | Tier | Relevant references | |
|
| 68 | +|:--------------------:|:----:|:------------------------------------------------------------------------------| |
|
| 69 | +| [ABCA3](ABCA3) | 2 | Beà et al. 2013 | |
|
| 70 | +| [ABCC9](ABCC9) | 2 | Beà et al. 2013 | |
|
| 71 | +| [ANK2](ANK2) | 2 | Zhang et al. 2014 | |
|
| 72 | +| [ARID1B](ARID1B) | 2 | Reddy et al. 2017 | |
|
| 73 | +| [ATP11C](ATP11C) | 2 | Zhang et al. 2014 | |
|
| 74 | +| [B2M](B2M) | 2 | Pararajalingam et al. 2020; Reichel et al. 2015; Morin et al. 2011 | |
|
| 75 | +| [BCOR](BCOR) | 2 | Nadeu et al. 2020; Jallades et al. 2017 | |
|
| 76 | +| [CDH8](CDH8) | 2 | Zhang et al. 2014 | |
|
| 77 | +| [CHMP4C](CHMP4C) | 2 | Beà et al. 2013 | |
|
| 78 | +| [COL11A1](COL11A1) | 2 | Zhang et al. 2014 | |
|
| 79 | +| [COL16A1](COL16A1) | 2 | Zhang et al. 2014 | |
|
| 80 | +| [CRYBG3](CRYBG3) | 2 | Beà et al. 2013 | |
|
| 81 | +| [CTNNA2](CTNNA2) | 2 | Zhang et al. 2014 | |
|
| 82 | +| [DCP1B](DCP1B) | 2 | Beà et al. 2013 | |
|
| 83 | +| [DHDH](DHDH) | 2 | Zhang et al. 2014 | |
|
| 84 | +| [DLC1](DLC1) | 2 | Zhang et al. 2014 | |
|
| 85 | +| [DLGAP2](DLGAP2) | 2 | Beà et al. 2013 | |
|
| 86 | +| [DNAJC6](DNAJC6) | 2 | Beà et al. 2013 | |
|
| 87 | +| [EIF2AK4](EIF2AK4) | 2 | Zhang et al. 2014 | |
|
| 88 | +| [ESX1](ESX1) | 2 | Zhang et al. 2014 | |
|
| 89 | +| [FAT4](FAT4) | 2 | Parry et al. 2013; Zhang et al. 2014; Morin et al. 2013 | |
|
| 90 | +| [GRIN2A](GRIN2A) | 2 | Zhang et al. 2014 | |
|
| 91 | +| [HEPH](HEPH) | 2 | Zhang et al. 2014 | |
|
| 92 | +| [KCNC2](KCNC2) | 2 | Beà et al. 2013 | |
|
| 93 | +| [KIAA1671](KIAA1671) | 2 | Beà et al. 2013 | |
|
| 94 | +| [KMT2C](KMT2C) | 2 | Sarkozy et al. 2021; Zhang et al. 2014; Zhang et al. 2013; Zhou et al. 2019 | |
|
| 95 | +| [LUZP4](LUZP4) | 2 | Beà et al. 2013 | |
|
| 96 | +| [MRGPRF](MRGPRF) | 2 | Zhang et al. 2014 | |
|
| 97 | +| [NIN](NIN) | 2 | Zhang et al. 2014 | |
|
| 98 | +| [OGDHL](OGDHL) | 2 | Zhang et al. 2014 | |
|
| 99 | +| [PCDHB2](PCDHB2) | 2 | Zhang et al. 2014 | |
|
| 100 | +| [PCSK2](PCSK2) | 2 | Beà et al. 2013 | |
|
| 101 | +| [PDLIM3](PDLIM3) | 2 | Beà et al. 2013 | |
|
| 102 | +| [PLXNB3](PLXNB3) | 2 | Spina et al. 2016; Zhang et al. 2014 | |
|
| 103 | +| [RGS4](RGS4) | 2 | Beà et al. 2013 | |
|
| 104 | +| [ROBO2](ROBO2) | 2 | Zhang et al. 2014 | |
|
| 105 | +| [SALL3](SALL3) | 2 | Love et al. 2012; Zhang et al. 2014 | |
|
| 106 | +| [SI](SI) | 2 | Zhang et al. 2014 | |
|
| 107 | +| [SLC17A6](SLC17A6) | 2 | Beà et al. 2013 | |
|
| 108 | +| [SMARCB1](SMARCB1) | 2 | Nadeu et al. 2020 | |
|
| 109 | +| [SMC1A](SMC1A) | 2 | Zhang et al. 2014 | |
|
| 110 | +| [TBC1D26](TBC1D26) | 2 | Zhang et al. 2014 | |
|
| 111 | +| [TNRC6B](TNRC6B) | 2 | Beà et al. 2013 | |
|
| 112 | +| [TRPM6](TRPM6) | 2 | Beà et al. 2013 | |
|
| 113 | +| [ZNF117](ZNF117) | 2 | Zhang et al. 2014 | |
|
| 114 | +| [ZNF296](ZNF296) | 2 | Zhang et al. 2014 | |
|
| 115 | 115 | |
| 116 | 116 | # References |
| 117 | 117 | |
| ... | ... | @@ -137,6 +137,17 @@ the National Academy of Sciences* 110 45: 18250–55. |
| 137 | 137 | |
| 138 | 138 | </div> |
| 139 | 139 | |
| 140 | +<div id="ref-braggioGenomicAnalysisMarginal2012" class="csl-entry"> |
|
| 141 | + |
|
| 142 | +Braggio, Esteban, Ahmet Dogan, Jonathan J. Keats, Wee J. Chng, Gaofeng |
|
| 143 | +Huang, Julie M. Matthews, Matthew J. Maurer, et al. 2012. “Genomic |
|
| 144 | +Analysis of Marginal Zone and Lymphoplasmacytic Lymphomas Identified |
|
| 145 | +Common and Disease-Specific Abnormalities.” *Modern Pathology: An |
|
| 146 | +Official Journal of the United States and Canadian Academy of Pathology, |
|
| 147 | +Inc* 25 5: 651–60. <https://doi.org/10.1038/modpathol.2011.213>. |
|
| 148 | + |
|
| 149 | +</div> |
|
| 150 | + |
|
| 140 | 151 | <div id="ref-chapuyMolecularSubtypesDiffuse2018b" class="csl-entry"> |
| 141 | 152 | |
| 142 | 153 | Chapuy, Bjoern, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Atanas |
| ... | ... | @@ -147,6 +158,24 @@ Pathogenic Mechanisms and Outcomes.” *Nature Medicine* 24 5: 679–90. |
| 147 | 158 | |
| 148 | 159 | </div> |
| 149 | 160 | |
| 161 | +<div id="ref-deschGenotypingCirculatingTumor2020" class="csl-entry"> |
|
| 162 | + |
|
| 163 | +Desch, Ann-Kathrin, Kristin Hartung, Ante Botzen, Alexander Brobeil, |
|
| 164 | +Mathias Rummel, Lars Kurch, Thomas Georgi, et al. 2020. “Genotyping |
|
| 165 | +Circulating Tumor DNA of Pediatric Hodgkin Lymphoma.” *Leukemia* 34 1: |
|
| 166 | +151–66. <https://doi.org/10.1038/s41375-019-0541-6>. |
|
| 167 | + |
|
| 168 | +</div> |
|
| 169 | + |
|
| 170 | +<div id="ref-dunsCharacterizationDLBCLPMBL2021b" class="csl-entry"> |
|
| 171 | + |
|
| 172 | +Duns, Gerben, Elena Viganò, Daisuke Ennishi, Clementine Sarkozy, Stacy |
|
| 173 | +S. Hung, Elizabeth Chavez, Katsuyoshi Takata, et al. 2021. |
|
| 174 | +“Characterization of DLBCL with a PMBL Gene Expression Signature.” |
|
| 175 | +*Blood* 138 2: 136–48. <https://doi.org/10.1182/blood.2020007683>. |
|
| 176 | + |
|
| 177 | +</div> |
|
| 178 | + |
|
| 150 | 179 | <div id="ref-grandeGenomewideDiscoverySomatic2019" class="csl-entry"> |
| 151 | 180 | |
| 152 | 181 | Grande, Bruno M., Daniela S. Gerhard, Aixiang Jiang, Nicholas B. Griner, |
| ... | ... | @@ -157,6 +186,17 @@ Pediatric Endemic and Sporadic Burkitt Lymphoma.” *Blood* 133 12: |
| 157 | 186 | |
| 158 | 187 | </div> |
| 159 | 188 | |
| 189 | +<div id="ref-jalladesExomeSequencingIdentifies2017" class="csl-entry"> |
|
| 190 | + |
|
| 191 | +Jallades, Laurent, Lucile Baseggio, Pierre Sujobert, Sarah Huet, Kaddour |
|
| 192 | +Chabane, Evelyne Callet-Bauchu, Aurélie Verney, et al. 2017. “Exome |
|
| 193 | +Sequencing Identifies Recurrent BCOR Alterations and the Absence of |
|
| 194 | +KLF2, TNFAIP3 and MYD88 Mutations in Splenic Diffuse Red Pulp Small |
|
| 195 | +<span class="nocase">B-cell</span> Lymphoma.” *Haematologica* 102 10: |
|
| 196 | +1758–66. <https://doi.org/10.3324/haematol.2016.160192>. |
|
| 197 | + |
|
| 198 | +</div> |
|
| 199 | + |
|
| 160 | 200 | <div id="ref-krysiakRecurrentSomaticMutations2017b" class="csl-entry"> |
| 161 | 201 | |
| 162 | 202 | Krysiak, Kilannin, Felicia Gomez, Brian S. White, Matthew Matlock, |
| ... | ... | @@ -186,6 +226,16 @@ Mutations in Burkitt Lymphoma.” *Nature Genetics* 44 12: 1321–25. |
| 186 | 226 | |
| 187 | 227 | </div> |
| 188 | 228 | |
| 229 | +<div id="ref-mansouriFrequentNFKBIEDeletions2016" class="csl-entry"> |
|
| 230 | + |
|
| 231 | +Mansouri, Larry, Daniel Noerenberg, Emma Young, Elena Mylonas, Maysaa |
|
| 232 | +Abdulla, Mareike Frick, Fazila Asmar, et al. 2016. “Frequent NFKBIE |
|
| 233 | +Deletions Are Associated with Poor Outcome in Primary Mediastinal <span |
|
| 234 | +class="nocase">B-cell</span> Lymphoma.” *Blood* 128 23: 2666–70. |
|
| 235 | +<https://doi.org/10.1182/blood-2016-03-704528>. |
|
| 236 | + |
|
| 237 | +</div> |
|
| 238 | + |
|
| 189 | 239 | <div id="ref-morinGeneticLandscapesRelapsed2016" class="csl-entry"> |
| 190 | 240 | |
| 191 | 241 | Morin, Ryan D., Sarit Assouline, Miguel Alcaide, Arezoo Mohajeri, |
| ... | ... | @@ -246,6 +296,16 @@ Exome and Genome Sequencing.” *Blood* 136 5: 572–84. |
| 246 | 296 | |
| 247 | 297 | </div> |
| 248 | 298 | |
| 299 | +<div id="ref-parryWholeExomeSequencing2013" class="csl-entry"> |
|
| 300 | + |
|
| 301 | +Parry, Marina, Matthew J. J. Rose-Zerilli, Jane Gibson, Sarah Ennis, |
|
| 302 | +Renata Walewska, Jade Forster, Helen Parker, et al. 2013. “Whole Exome |
|
| 303 | +Sequencing Identifies Novel Recurrently Mutated Genes in Patients with |
|
| 304 | +Splenic Marginal Zone Lymphoma.” *PloS One* 8 12: e83244. |
|
| 305 | +<https://doi.org/10.1371/journal.pone.0083244>. |
|
| 306 | + |
|
| 307 | +</div> |
|
| 308 | + |
|
| 249 | 309 | <div id="ref-pasqualucciAnalysisCodingGenome2011" class="csl-entry"> |
| 250 | 310 | |
| 251 | 311 | Pasqualucci, Laura, Vladimir Trifonov, Giulia Fabbri, Jing Ma, Davide |
| ... | ... | @@ -265,6 +325,16 @@ and Functional Drivers of Diffuse Large B Cell Lymphoma.” *Cell* 171 |
| 265 | 325 | |
| 266 | 326 | </div> |
| 267 | 327 | |
| 328 | +<div id="ref-reichelFlowSortingExome2015a" class="csl-entry"> |
|
| 329 | + |
|
| 330 | +Reichel, Jonathan, Amy Chadburn, Paul G. Rubinstein, Lisa Giulino-Roth, |
|
| 331 | +Wayne Tam, Yifang Liu, Rafael Gaiolla, et al. 2015. “Flow Sorting and |
|
| 332 | +Exome Sequencing Reveal the Oncogenome of Primary Hodgkin and |
|
| 333 | +Reed-Sternberg Cells.” *Blood* 125 7: 1061–72. |
|
| 334 | +<https://doi.org/10.1182/blood-2014-11-610436>. |
|
| 335 | + |
|
| 336 | +</div> |
|
| 337 | + |
|
| 268 | 338 | <div id="ref-richterRecurrentMutationID32012a" class="csl-entry"> |
| 269 | 339 | |
| 270 | 340 | Richter, Julia, Matthias Schlesner, Steve Hoffmann, Markus Kreuz, Ellen |
| ... | ... | @@ -275,6 +345,56 @@ Genome, Exome and Transcriptome Sequencing.” *Nature Genetics* 44 12: |
| 275 | 345 | |
| 276 | 346 | </div> |
| 277 | 347 | |
| 348 | +<div id="ref-rossiAlterationBIRC3Multiple2011a" class="csl-entry"> |
|
| 349 | + |
|
| 350 | +Rossi, Davide, Silvia Deaglio, David Dominguez-Sola, Silvia Rasi, |
|
| 351 | +Tiziana Vaisitti, Claudio Agostinelli, Valeria Spina, et al. 2011. |
|
| 352 | +“Alteration of BIRC3 and Multiple Other <span |
|
| 353 | +class="nocase">NF-κB</span> Pathway Genes in Splenic Marginal Zone |
|
| 354 | +Lymphoma.” *Blood* 118 18: 4930–34. |
|
| 355 | +<https://doi.org/10.1182/blood-2011-06-359166>. |
|
| 356 | + |
|
| 357 | +</div> |
|
| 358 | + |
|
| 359 | +<div id="ref-rossiCodingGenomeSplenic2012c" class="csl-entry"> |
|
| 360 | + |
|
| 361 | +Rossi, Davide, Vladimir Trifonov, Marco Fangazio, Alessio Bruscaggin, |
|
| 362 | +Silvia Rasi, Valeria Spina, Sara Monti, et al. 2012. “The Coding Genome |
|
| 363 | +of Splenic Marginal Zone Lymphoma: Activation of NOTCH2 and Other |
|
| 364 | +Pathways Regulating Marginal Zone Development.” *The Journal of |
|
| 365 | +Experimental Medicine* 209 9: 1537–51. |
|
| 366 | +<https://doi.org/10.1084/jem.20120904>. |
|
| 367 | + |
|
| 368 | +</div> |
|
| 369 | + |
|
| 370 | +<div id="ref-sarkozyMutationalLandscapeGray2021a" class="csl-entry"> |
|
| 371 | + |
|
| 372 | +Sarkozy, Clémentine, Stacy S. Hung, Elizabeth A. Chavez, Gerben Duns, |
|
| 373 | +Katsuyoshi Takata, Lauren C. Chong, Tomohiro Aoki, et al. 2021. |
|
| 374 | +“Mutational Landscape of Gray Zone Lymphoma.” *Blood* 137 13: 1765–76. |
|
| 375 | +<https://doi.org/10.1182/blood.2020007507>. |
|
| 376 | + |
|
| 377 | +</div> |
|
| 378 | + |
|
| 379 | +<div id="ref-spinaGeneticsNodalMarginal2016b" class="csl-entry"> |
|
| 380 | + |
|
| 381 | +Spina, Valeria, Hossein Khiabanian, Monica Messina, Sara Monti, Luciano |
|
| 382 | +Cascione, Alessio Bruscaggin, Elisa Spaccarotella, et al. 2016. “The |
|
| 383 | +Genetics of Nodal Marginal Zone Lymphoma.” *Blood* 128 10: 1362–73. |
|
| 384 | +<https://doi.org/10.1182/blood-2016-02-696757>. |
|
| 385 | + |
|
| 386 | +</div> |
|
| 387 | + |
|
| 388 | +<div id="ref-tiacciPervasiveMutationsJAKSTAT2018b" class="csl-entry"> |
|
| 389 | + |
|
| 390 | +Tiacci, Enrico, Erik Ladewig, Gianluca Schiavoni, Alex Penson, |
|
| 391 | +Elisabetta Fortini, Valentina Pettirossi, Yuchun Wang, et al. 2018. |
|
| 392 | +“Pervasive Mutations of JAK-STAT Pathway Genes in Classical Hodgkin |
|
| 393 | +Lymphoma.” *Blood* 131 22: 2454–65. |
|
| 394 | +<https://doi.org/10.1182/blood-2017-11-814913>. |
|
| 395 | + |
|
| 396 | +</div> |
|
| 397 | + |
|
| 278 | 398 | <div id="ref-troenNOTCH2MutationsMarginal2008" class="csl-entry"> |
| 279 | 399 | |
| 280 | 400 | Trøen, Gunhild, Iwona Wlodarska, Abdirashid Warsame, Silvia Hernández |
| ... | ... | @@ -304,6 +424,17 @@ Recurrent CARD11 Mutations.” *Oncotarget* 7 25: 38180–90. |
| 304 | 424 | |
| 305 | 425 | </div> |
| 306 | 426 | |
| 427 | +<div id="ref-yanBCRTLRSignaling2012a" class="csl-entry"> |
|
| 428 | + |
|
| 429 | +Yan, Qingguo, Yuanxue Huang, A. James Watkins, Sylvia Kocialkowski, |
|
| 430 | +Naiyan Zeng, Rifat A. Hamoudi, Peter G. Isaacson, Laurence de Leval, |
|
| 431 | +Andrew Wotherspoon, and Ming-Qing Du. 2012. “BCR and TLR Signaling |
|
| 432 | +Pathways Are Recurrently Targeted by Genetic Changes in Splenic Marginal |
|
| 433 | +Zone Lymphomas.” *Haematologica* 97 4: 595–98. |
|
| 434 | +<https://doi.org/10.3324/haematol.2011.054080>. |
|
| 435 | + |
|
| 436 | +</div> |
|
| 437 | + |
|
| 307 | 438 | <div id="ref-zhangGeneticHeterogeneityDiffuse2013" class="csl-entry"> |
| 308 | 439 | |
| 309 | 440 | Zhang, Jenny, Vladimir Grubor, Cassandra L Love, Anjishnu Banerjee, |
MKI67.md
| ... | ... | @@ -47,7 +47,7 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/M |
| 47 | 47 |  |
| 48 | 48 | <!-- ORIGIN: schmitzBurkittLymphomaPathogenesis2012 --> |
| 49 | 49 | <!-- BL: schmitzBurkittLymphomaPathogenesis2012 --> |
| 50 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 50 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 51 | 51 | ## References |
| 52 | 52 | 1. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012 Oct 4;490(7418):116–120. PMCID: PMC3609867 |
| 53 | 53 | 2. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |
NFKBIA.md
| ... | ... | @@ -55,7 +55,7 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/N |
| 55 | 55 | |
| 56 | 56 | <!-- ORIGIN: lakeMutationsNFKBIAEncoding2009 --> |
| 57 | 57 | <!-- DLBCL: lakeMutationsNFKBIAEncoding2009 --> |
| 58 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 58 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 59 | 59 | <!-- PMBL: wienandGenomicAnalysesFlowsorted2019b --> |
| 60 | 60 | ## References |
| 61 | 61 | 1. Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, Wang JQ, Schmitz R, Morin RD, Tang J, Jiang A, Bagaev A, Plotnikova O, Kotlov N, Johnson CA, Wilson WH, Scott DW, Staudt LM. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020 Apr 13;37(4):551-568.e14. doi: 10.1016/j.ccell.2020.03.015. PMID: 32289277; PMCID: PMC8459709. |
OR8H2.md
| ... | ... | @@ -38,6 +38,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/O |
| 38 | 38 | ## OR8H2 Expression |
| 39 | 39 |  |
| 40 | 40 | <!-- ORIGIN: russler-germainMutationsAssociatedProgression2023a --> |
| 41 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 41 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 42 | 42 | ## References |
| 43 | 43 | 1. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |
PZP.md
| ... | ... | @@ -38,6 +38,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/P |
| 38 | 38 | ## PZP Expression |
| 39 | 39 |  |
| 40 | 40 | <!-- ORIGIN: russler-germainMutationsAssociatedProgression2023a --> |
| 41 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 41 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 42 | 42 | ## References |
| 43 | 43 | 1. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |
SHROOM3.md
| ... | ... | @@ -39,6 +39,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/S |
| 39 | 39 | ## SHROOM3 Expression |
| 40 | 40 |  |
| 41 | 41 | <!-- ORIGIN: russler-germainMutationsAssociatedProgression2023a --> |
| 42 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 42 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 43 | 43 | ## References |
| 44 | 44 | 1. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |
SRRM2.md
| ... | ... | @@ -45,7 +45,7 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/S |
| 45 | 45 |  |
| 46 | 46 | <!-- ORIGIN: morinMutationalStructuralAnalysis2013 --> |
| 47 | 47 | <!-- DLBCL: morinMutationalStructuralAnalysis2013 --> |
| 48 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 48 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 49 | 49 | ## References |
| 50 | 50 | 1. Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A, Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL, Johnson NA, Shah S, Jones S, Steidl C, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013 Aug 15;122(7):1256–1265. PMCID: PMC3744992 |
| 51 | 51 | 2. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |
STAB2.md
| ... | ... | @@ -38,6 +38,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/S |
| 38 | 38 | ## STAB2 Expression |
| 39 | 39 |  |
| 40 | 40 | <!-- ORIGIN: russler-germainMutationsAssociatedProgression2023a --> |
| 41 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 41 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 42 | 42 | ## References |
| 43 | 43 | 1. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |
XIRP2.md
| ... | ... | @@ -47,6 +47,6 @@ View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/X |
| 47 | 47 | ## XIRP2 Expression |
| 48 | 48 |  |
| 49 | 49 | <!-- ORIGIN: russler-germainMutationsAssociatedProgression2023a --> |
| 50 | -<!-- FL: russler-germainMutationsAssociatedProgression2023a --> |
|
| 50 | +<!-- FL: russler-germainMutationsAssociatedProgression2023b --> |
|
| 51 | 51 | ## References |
| 52 | 52 | 1. Russler-Germain DA, Krysiak K, Ramirez CA, Mosior M, Watkins MP, Gomez F, Skidmore ZL, Trani L, Gao F, Geyer S, Cashen A, Mehta-Shah N, Kahl B, Bartlett N, Alderuccio J, Lossos I, Ondrejka S, Hsi E, Martin P, Leonard J, Griffith M, Griffith O, Fehniger T. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Advances. 2023;7:5524–5539. |